<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050189</url>
  </required_header>
  <id_info>
    <org_study_id>2020-3242</org_study_id>
    <nct_id>NCT04050189</nct_id>
  </id_info>
  <brief_title>Validation of the In-utero Transmission of Probiotics</brief_title>
  <acronym>PROBIO</acronym>
  <official_title>Validation of the In-utero Transmission of Probiotics From the Mother to the Baby: A Randomized Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lallemand Health Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot project aims at confirming the in-utero transmission of probiotics, from the
      mother to the baby. Women aged 18 to 42 years, with a single pregnancy, considered low risk
      will be approached for this study. Women will take the investigational products between 34
      weeks of pregnancy up to 10 days post-partum. Investigational products are probiotics (5
      bacterial strains) compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational: Studies have shown that probiotics given to babies can reduce perinatal
      complications. A change of practice should therefore be introduced in the management of
      premature newborns. However, one could assume that probiotic administration before birth
      could be as effective if not more. Indeed, one could hypothesise that when the newborn is
      exposed to probiotics earlier, the protective effect is potentially increased.

      Objective: This pilot project aims at confirming the in-utero transmission of probiotics,
      from the mother to the baby.

      Population: Women aged 18 to 42 years, with a single pregnancy, considered low risk will be
      approached for this study Products under study: Probiotics containing 5 bacterial strains
      (total of 12 million colony-forming unit / day) vs. Placebo.

      Procedure: At 32-33 weeks, participants will complete questionnaires (medical, obstetrical,
      socio-demographic data) and will be randomized (double-blind) in one of the 2 following
      groups:

      Group A: taking probiotics every day from the 34th week of pregnancy until delivery; taking
      placebo for 10 days after delivery.

      Group B: taking placebo every day from the 34th week of pregnancy until delivery; taking
      probiotics for 10 days after delivery.

      Follow-up: All women will complete a logbook to monitor the study products intake and monitor
      side effects until the end of the study (10 days postpartum).

      Samples: maternal stool samples, vaginal secretions, stool (and meconium) as well as breast
      milk (and colostrum) will be taken at different times of the study to confirm the presence of
      probiotics and transmission between the mother and the baby.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2-arms randomized crossover pilot study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>in-utero transmission of probiotic</measure>
    <time_frame>at birth</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in neonate meconium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to colostrum</measure>
    <time_frame>at birth</time_frame>
    <description>presence(yes or no) of probiotic (specific bacterial strains) in colostrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to maternal milk</measure>
    <time_frame>10 days postpartum</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in breastmilk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to maternal vaginal tract</measure>
    <time_frame>37 weeks of gestation</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in maternal vaginal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to maternal gut</measure>
    <time_frame>37 weeks of gestation</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in maternal stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postnatal transmission of probiotic to the neonate</measure>
    <time_frame>10 days postpartum</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in neonate stools</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>In Utero Drug Exposure</condition>
  <arm_group>
    <arm_group_label>prenatal probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postnatal probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natural products: Probiotics</intervention_name>
    <description>Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum</description>
    <arm_group_label>postnatal probiotic</arm_group_label>
    <arm_group_label>prenatal probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum</description>
    <arm_group_label>postnatal probiotic</arm_group_label>
    <arm_group_label>prenatal probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a single pregnancy

          -  Women with a low risk pregnancy

          -  Women wishing to breastfeed at birth

          -  Women randomized between 32 0/7 - 33 6/7 weeks of gestation

        Exclusion Criteria:

          -  History of obstetric complications (prematurity &lt;37 weeks, severe preeclampsia ,
             gestational diabetes treated with insulin)

          -  Obstetric or fetal complications known for current pregnancy such as threaten preterm
             labor (premature rupture of membranes or preterm labor), chorioamnionitis, placenta
             previa, active vaginal bleeding, cervical cerclage, fetal distress or anomalies,
             corticosteroid therapy

          -  Risk factors for obstetric complications during current pregnancy such as gestational
             diabetes, type I / II diabetes and high blood pressure (systole ≥140 and diastole ≥90)

          -  Antibiotic use within 2 weeks before randomisation

          -  Intake of probiotics or foods enriched with active cultures (fermented milk, kefir,
             kombucha ...) within 2 weeks before randomisation

          -  Women positive for Group B Streptococcus during previous pregnancies

          -  Weakened immune system (AIDS, lymphoma, chemoradiotherapy or corticotherapy,
             immunosuppressive pathology)

          -  Allergy or intolerance to lactose, soy or yeast.

          -  Women under Coumadin

          -  Women who plan to give birth outside the participating center

          -  Women who do not plan to breastfeed or extract their milk in the first 10 days after
             delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Pasquier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS-Estrie-CHUS hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amelie Tetu</last_name>
    <phone>8193461110</phone>
    <phone_ext>15571</phone_ext>
    <email>amelie.tetu.ciussse-chus@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Hamel-Thibault</last_name>
    <phone>8193461110</phone>
    <phone_ext>12865</phone_ext>
    <email>Audrey.Hamel-Thibault@USherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de L'Estrie-CHUS Hospital</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Amelie Tetu</last_name>
      <phone>8193461110</phone>
      <phone_ext>15571</phone_ext>
      <email>amelie.tetu.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Audrey Hamel-Thibault</last_name>
      <phone>8193461110</phone>
      <phone_ext>12865</phone_ext>
      <email>Audrey.Hamel-Thibault@USherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Charles Pasquier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Francois Beaulieu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>in-utero transmission</keyword>
  <keyword>pilot study</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a pilot study. Samples and data will be used to confirm the principal hypothesis and explorative secondary objectives.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

